(Q44765974)

English

Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region

scientific article published in January 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

head and neck squamous cell carcinoma

1 reference

based on heuristic

inferred from title

disseminated squamous cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jens D Bentzen

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Hanne Sand Hansen

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

publication date

1 January 2007

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

47-51

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FHED.20462

7 January 2021

based on heuristic

inferred from DOI database lookup

Single agent paclitaxel in advanced squamous cell head and neck carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHED.20462

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FHED.20462

7 January 2021

based on heuristic

inferred from DOI database lookup

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1002%2FHED.20462

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FHED.20462

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FHED.20462

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FHED.20462

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://api.crossref.org/works/10.1002%2FHED.20462

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FHED.20462

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FHED.20462

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HED.20462

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44765974&oldid=2039485844"